Zacks: Omeros Receives Average Rating of “Strong Buy” from Analysts (NASDAQ:OMER)
March 24th, 2015
Omeros (NASDAQ:OMER) has earned an average broker rating score of 1.20 (Strong Buy) from the five analysts that provide coverage for the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a buy rating and four have given a strong buy rating to the company. Omeros’ rating score has improved by 20% from 90 days ago as a result of various analysts’ upgrades and downgrades.
Analysts have set a 1-year consensus price target of $38.50 for the company and are forecasting that the company will post ($0.66) EPS for the current quarter, according to Zacks. Zacks has also given Omeros an industry rank of 112 out of 265 based on the ratings given to related companies.
Posted by Reagan on Mar 13th, 2015
Investment analysts at MLV & Co
set a $38.00 target price on shares of Omeros (NASDAQ:OMER) stock in a note issued to investors on Friday. The firm currently has a a “buy” rating on the stock. MLV & Co‘s price target suggests a potential upside of 50.73% from the stock’s previous close.
Omeros (NASDAQ:OMER) traded up 2.81% on Friday, hitting $25.21. 313,561 shares of the company’s stock traded hands. Omeros has a 52-week low of $9.76 and a 52-week high of $27.64. The stock’s 50-day moving average is $22. and its 200-day moving average is $18.. The company’s market cap is $859.03 million.
A number of other analysts have also recently weighed in on OMER. Analysts at Maxim Group raised their price target on shares of Omeros from $28.00 to $30.00 and gave the company a “buy” rating in a research note on Friday, February 20th. Analysts at Wedbush set a $52.00 price target on shares of Omeros and gave the company a “buy” rating in a research note on Thursday, February 19th. Finally, analysts at Zacks upgraded shares of Omeros from a “neutral” rating to an “outperform” rating and set a $25.40 price target on the stock in a research note on Monday, February 2nd. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Omeros currently has a consensus rating of “Buy” and a consensus price target of $32.90.
Omeros Corporation operates as a biopharmaceutical company focused on the discovery, development and commercialization of products focused on inflammation and disorders of the central nervous system. The Company develops pharmaceutical and therapeutic approaches to the management of surgical pain and inflammation, vasospasm, smooth muscle spasm, vascular restenosis and implantable surgical devices.
SEATTLE, March 9, 2015 /PRNewswire/ -- Omeros Corporation OMER, -4.36% a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced that the company will issue its fourth quarter and full-year 2014 financial results for the period ended December 31, 2014, on Monday, March 16, 2015, after market close. Omeros management will host a conference call and webcast that day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results.
Conference Call Details
To access the live conference call via phone, please dial (844) 831-4029 from the United States and Canada or (920) 663-6278 internationally. The participant passcode is 1480892. Please dial in approximately 10 minutes prior to the start of the call. A telephone replay will be available for one week following the call and may be accessed by dialing (855) 859-2056 from the United States and Canada or (404) 537-3406 internationally. The replay passcode is 1480892
From OMER's website.
OMS201 is being developed for use during urological procedures. OMS201 is a proprietary combination of an anti-inflammatory agent and a smooth muscle relaxant. Both active agents are contained in generic, FDA-approved drugs with well-known profiles of safety and pharmacologic activities, and each is contained in drugs that have been marketed in the U.S. for more than 15 years.
Added to standard irrigation solutions in urological procedures, OMS201 is delivered directly to sites of inflammation or surgical procedures. For example, OMS201 may be used during uroendoscopic procedures, such as bladder endoscopy, minimally invasive prostate surgery and ureteroscopy, to inhibit surgically induced inflammation, pain and smooth muscle spasm.
(More info on the website)
Where did you come up with no 10-K? Look for OMER's 2014 10-K by the end of next week, right on schedule.
Old news jbg? This is different from the MSC Microcap index rebalancing that took place at Friday's close. However, I'm thinking yesterday's big volume was shares being collected for this rebalancing, in which case we likely will not see a bump today. Either way, we'll know soon .......
AECOS Winter Symposium
March 01-04, 2015
St Regis Hotel, Aspen, Colorado
The American-European Congress of Ophthalmic Surgery® welcomes you to the AECOS Winter Symposium. This dynamic conference, evolved from the Dulaney-Aspen Invitational Refractive Symposium which began 30 years ago, is the legacy AECOS meeting. Convened annually in Aspen, the AECOS Winter Symposium assembles ophthalmologists, scientists, entrepreneurs and industry experts to debate and direct innovation in anterior segment surgery. The AECOS Winter Symposium celebrates a rich history of technology debuts, including laser refractive surgery, femtosecond lasers for LASIK, and laser cataract surgery.
OMER is a Gold sponsor of this event which should focus on Omidria as it is launched in the USA.
Certainly more than three .....
"All patients in this study cohort received OMS721 and improvements were observed across TMA disease markers. The investigators treating all of these patients at different sites consider the improvements to be treatment-related and clinically meaningful."
- The Company Agrees to Physician Request to Continue Treatment of Patients with aHUS -
SEATTLE, Feb. 19, 2015 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that it has completed dosing of the low-dose cohort of patients in its ongoing Phase 2 clinical trial evaluating the efficacy and safety of OMS721, the lead human monoclonal antibody for its mannan-binding lectin-associated serine protease-2 (MASP-2) program, in treating thrombotic microangiopathies (TMAs). TMAs are a family of rare, debilitating and life-threatening disorders characterized by excessive thrombi (clots) in the microcirculation of the body's organs, most commonly the kidney and brain. All patients in this study cohort received OMS721 and improvements were observed across TMA disease markers. The investigators treating all of these patients at different sites consider the improvements to be treatment-related and clinically meaningful. Based on observations in this cohort, a European investigator has requested that Omeros provide extended access to OMS721 for compassionate use in his two study patients, both of whom suffer from atypical hemolytic uremic syndrome (aHUS), a form of TMA.
In the clinical trial, the first cohort consisted of three patients treated with the lowest dose of OMS721. All three patients have aHUS. Platelet count, serum lactate dehydrogenase (LDH), and serum haptoglobin were measured as markers of disease activity. When compared to baseline levels, platelet counts improved in all patients. Serum LDH levels remained normal in one patient, substantially decreased to close to the normal range in another and remained elevated in the third. Haptoglobin improved in two patients, normalizing in one. Creatinine levels in the one patient with independent renal function also improved.
(more in the full PR)
The mean area-under-the-curve (AUC) difference (standard error) in VAS scores between subjects treated with OMS302 vs subjects treated with placebo was -4.94 mm (0.77) (95% CI: -6.44 to -3.44, p less than 0.001). Significantly more OMS302 subjects were pain free (VAS=0) at all postoperative evaluations (26.0% vs 17.2 %, p=0.0012) and significantly less OMS302 subjects had moderate to severe pain (VAS=40) at any time point (7.2% vs 14.4%, p=0.0005; respectively). Additionally, analgesic use on day of surgery was significantly lower for OMS302 subjects compared to placebo subjects (27.5% vs 37.1 %, p=0.0019, respectively).
OMS302 was associated with significantly less postoperative ocular pain and pain medication use on day of cataract surgery or intraocular lens replacement. Use of OMS302 in these settings may improve overall patient satisfaction with these procedures."
Yahoo really misbehaving. I can't post the full results and conclusion. The results were very good. Substantially less pain and analgesic use following surgery when Omidria is used.
At World Cornea Conference VII in San Diego ....
Reduction in Analgesic Use and Postoperative Ocular Pain With New Irrigating Solution During Cataract and IOL Replacement Procedures
Monday, April 20, 2015: 3:11 PM
Room 1B (San Diego Convention Center)
Edward J. Holland, MD, Cincinnati Eye Institute, Cincinnati, OH, USA
Alan S. Crandall, MD, John A. Moran Eye Center, Salt Lake City, Utah, USA
Steve Whitaker, MD, Omeros Corporation, Seattle, WA, USA
Post-hoc integrated analyses of subject-reported early postoperative pain and documented analgesic use following cataract and intraocular lens replacement (ILR) procedures – pooled data from three prospective, randomized controlled studies of OMS302 (Omidria [phenylephrine and ketorolac injection] 1%/0.3%).
Data from 3 prospective, controlled, randomized clinical studies of OMS302 in subjects undergoing cataract extraction/replacement or refractive lens exchange surgery were included in a pooled post-hoc and integrated analysis of 1) early postoperative ocular pain and 2) analgesic use on the day of the procedure. Early postoperative ocular pain was assessed by each subject using a visual analog scale (VAS) at the following time points: 2, 4, 6, 8, and 10–12 hours after surgery. Analgesic use on day of surgery was recorded. A total of 919 subjects (461 placebo and 458 OMS302) were included.
(see reply for Results and Conclusion)
New SC 13G/A filing today .........
Item 4. Ownership.
(a) Amount beneficially owned:
(b) Percent of class:
Item 6. Ownership of More Than Five Percent on Behalf of Another Person.
Ingalls & Snyder, LLC ("I&S") is a registered broker dealer and a
registered investment advisor. Shares reported under shared
dispositive power include shares held in accounts managed under
investment advisory contracts.
Omeros Closes $84 Million Public Offering of Common Stock and Pre-Funded Warrants
SEATTLE, Feb. 3, 2015 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that it has closed the underwritten public offering that was priced and allocated to investors on January 28, 2015 relating to the sale of 3,444,831 shares of its common stock at a price of $20.03 per share and 749,250 pre-funded warrants to purchase up to an equal number of shares of its common stock at a price per warrant of $20.02, which was paid at closing. The pre-funded warrants have an exercise price of $0.01 per share and will expire on February 3, 2022. Gross proceeds from the offering were approximately $84.0 million, including approximately $15.0 million from the sale of the pre-funded warrants. The closing also included the sale of 449,325 shares of common stock sold pursuant to the option allowing the underwriters to purchase additional shares of common stock from Omeros, which the underwriters exercised in full. After deducting underwriting discounts and other estimated offering expenses, Omeros will receive net proceeds from the transaction of approximately $79.1 million.
Cowen and Company, LLC acted as the sole book-running manager for the offering.
Wedbush PackGrow Life Sciences acted as co-lead manager. Needham & Company, LLC, Maxim Group LLC, WBB Securities LLC and MLV & Co. LLC acted as co-managers.
A shelf registration statement (File No. 333-201581) relating to these securities (including the shares issuable upon the exercise of the pre-funded warrants) was filed with the Securities and Exchange Commission on January 16, 2015 and was automatically effective upon filing. A final prospectus supplement related to the offering was filed with the Securities and Exchange Commission on January 30, 2015.
[More details in the full press release on the OMER website]
OMER filed an 8-K yesterday (Monday). All of the shares, warrants and over allotment shares have been sold. Full listing in the 8-K.